Composition for prevention or treatment of neurodegenerative diseases

A neurodegenerative, aqueous composition technology, used in neurological diseases, neuromuscular diseases, drug combinations, etc.

Inactive Publication Date: 2018-12-21
新粹尔私人有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs themselves have various side effects such as nausea, vomiting, diarrhea, muscle cramps, fatigue, weight loss, dizziness, decreased appetite, constipation, and headaches

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for prevention or treatment of neurodegenerative diseases
  • Composition for prevention or treatment of neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Creation of a composition comprising lutein.

[0047] Compositions comprising lutein were produced from eggs obtained by feeding lutein and zeaxanthin to chickens and collecting egg yolks from the eggs produced by these chickens (WO 2009 / 078716). These eggs are referred to herein as enriched eggs.

[0048] The feed used to produce enriched eggs is formulated and produced within the legal requirements for animal feed. The use of lutein and zeaxanthin is regulated in accordance with EU Regulation 1831 / 2003. The dosage of lutein and zeaxanthin in the feed does not exceed the legal limit of 80ppm in animal feed.

[0049] Poultry fed a feed rich in lutein and zeaxanthin produce enriched eggs containing 45mg-80mg of lutein per kilogram of yolk and 10mg-30mg of zeaxanthin per kilogram of yolk.

[0050] The animals were also fed a diet rich in omega-3 fatty acids; eggs contained about 200 mg omega-3 fatty acids per kg yolk with a standard deviation of 10 mg.

Embodiment 2

[0051] Example 2: Manufacture of an aqueous dispersion comprising lutein.

[0052] Eggs enriched with lutein and DHA were produced according to an ISO 22000 / HACCP certified quality scheme as described in Example 1. Eggs are separated into yolks and whites in an automated facility in ISO 22000:2005 certified equipment. Egg yolks from 165,000 enriched eggs were mixed with 5,500 liters of buttermilk containing 80 mg of polar lipid per liter and 170 kg of sugar (15 min, 4°C). The liquid was pasteurized at 65°C for 3 minutes and cooled to 4°C. This composition is referred to herein as NWT-02 or NWT-02 liquid formulation.

[0053] For storage, the composition was dried to a powder with a moisture content of 4% (± 1%) and mixed with a free-flowing agent (SiO 2 , Sipernat 22S) mixed.

Embodiment 3

[0054] Example 3: Preparation of protein hydrolysates comprising dipeptides and tripeptides.

[0055] A 5% (w / v) aqueous solution of lysozyme (100% protein content, Belovo SA, Bastogne, Belgium) was prepared and adjusted to a pH of 7.5 to 8.5 with 3M KOH . By adding Alcalase (Tm) (Novozymes) to a final concentration of 4% by protein to initiate hydrolysis. The solution was incubated at 60°C for a total of 5-6 hours with continuous agitation. Alcalase was then inactivated by raising the temperature to 90°C for 15 minutes. The solution was then cooled to 2°C and stored overnight with continuous stirring.

[0056] The resulting hydrolyzate solution was filtered through a 10 μm filter and then through a 1 μm filter. Afterwards, the filtrate was heat-treated at 135° C. for 15 seconds and concentrated to a dry matter of 57° Brix (about 45% dry matter) by means of a NIRO evaporator at a flow rate of 3300 liters / hour at 90° C. After evaporation, the product was spray dried to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention is in the field of the prevention, amelioration or treatment of neurodegenerative diseases, in particular of dementia including Alzheimer's disease, Huntington's disease, Parkinson's disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. The invention provides new compositions that allow an improved prevention, amelioration and treatment of such diseases. More in particular,the invention provides a composition comprising a xanthophyll and a hydrolysate of a protein, comprising di- and tripeptides.

Description

technical field [0001] The present invention is in the field of prevention, alleviation and treatment of neurodegenerative diseases, especially dementia, including vascular forms of dementia and Alzheimer's disease, Huntington's Disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis. The present invention provides novel compositions that allow improved prevention, alleviation and treatment of these diseases. Background technique [0002] Neurodegeneration is the term for a family of overlapping conditions that primarily affect neurons in the human brain. These conditions are currently incurable and result in progressive loss of structure and / or function of neurons, including death of these cells. They are caused by the failure of brain connections formed by neuron-neuron, neuron-glia and glia-glia contacts. Neurons are the structural units of the nervous system, which includes the brain and spinal cord. Neurons do not regenerate or replace the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/18A23L33/155A23L15/00
CPCA23L33/155A23L33/18A61P21/00A61P25/02A61P25/14A61P25/16A61P25/28A61P43/00A23V2002/00A23V2200/322A61K9/10A61K31/202A61K31/355A61K31/592A61K35/57A61K38/018A61K38/05A61K38/06A61K47/10
Inventor 保罗·里奥庞德·琼科尔塞纳·玛利亚·范德尔梅德卢卡斯·杰拉德斯·威利布罗德斯·斯特尔可曼
Owner 新粹尔私人有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap